Cypherpunk Technologies (formerly Leap Therapeutics)
Cambridge
About Cypherpunk Technologies (formerly Leap Therapeutics)
Cypherpunk Technologies is a biopharmaceutical company developing antibody therapies for cancer while simultaneously executing a digital-asset treasury strategy centered on Zcash. Their oncology pipeline includes sirexatamab (DKN-01), a monoclonal antibody targeting DKK-1, and FL-501, another antibody in preclinical development.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $325.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Oct 2025)
- Ticker: nasdaq:CYPH
- Website: cypherpunk.com
Industries & Categories
Biotechnology, FinTech, Life Science, Medical, Oncology
Social Profiles
Canonical: https://fsome.com/organization/cypherpunk-technologies-formerly-leap-therapeutics-72129 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.